| Dr Carl F Juneau, MD | |
|
1470 Medical Pkwy, Suite 160, Carson City, NV 89703-4648 | |
| (775) 445-7650 | |
| (775) 882-4206 |
| Full Name | Dr Carl F Juneau |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 48 Years |
| Location | 1470 Medical Pkwy, Carson City, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376560276 | NPI | - | NPPES |
| 1376560276 | Other | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 8494 (Nevada) | Primary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 8494 (Nevada) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hilo Medical Center | Hilo, HI | Hospital |
| Kau Hospital | Pahala, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hilo Medical Center | 1254422900 | 70 |
| Kau Hospital | 7416945548 | 88 |
News Archive
Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world's second leading cause of blindness.
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.
Malvern Instruments has launched two new-generation isothermal titration calorimeters (ITC), advancing its recently acquired MicroCal range to further support life science researchers studying biomolecular interactions. The new manual Malvern MicroCal PEAQ-ITC and fully automated Malvern MicroCal PEAQ-ITC Automatedsystems are designed to deliver the enhanced functionality and robust performance now demanded of this essential tool.
› Verified 7 days ago
| Entity Name | Kau Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144304338 PECOS PAC ID: 7416945548 Enrollment ID: O20040601000398 |
News Archive
Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world's second leading cause of blindness.
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.
Malvern Instruments has launched two new-generation isothermal titration calorimeters (ITC), advancing its recently acquired MicroCal range to further support life science researchers studying biomolecular interactions. The new manual Malvern MicroCal PEAQ-ITC and fully automated Malvern MicroCal PEAQ-ITC Automatedsystems are designed to deliver the enhanced functionality and robust performance now demanded of this essential tool.
› Verified 7 days ago
| Entity Name | Hilo Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962584060 PECOS PAC ID: 1254422900 Enrollment ID: O20070809000268 |
News Archive
Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world's second leading cause of blindness.
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.
Malvern Instruments has launched two new-generation isothermal titration calorimeters (ITC), advancing its recently acquired MicroCal range to further support life science researchers studying biomolecular interactions. The new manual Malvern MicroCal PEAQ-ITC and fully automated Malvern MicroCal PEAQ-ITC Automatedsystems are designed to deliver the enhanced functionality and robust performance now demanded of this essential tool.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Carl F Juneau, MD Po Box 4390, Carson City, NV 89702-4390 Ph: (775) 445-7650 | Dr Carl F Juneau, MD 1470 Medical Pkwy, Suite 160, Carson City, NV 89703-4648 Ph: (775) 445-7650 |
News Archive
Emergent BioSolutions Inc. announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed at bedside, have been published in Vaccine, a leading medical journal on vaccines and immunology.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world's second leading cause of blindness.
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.
Malvern Instruments has launched two new-generation isothermal titration calorimeters (ITC), advancing its recently acquired MicroCal range to further support life science researchers studying biomolecular interactions. The new manual Malvern MicroCal PEAQ-ITC and fully automated Malvern MicroCal PEAQ-ITC Automatedsystems are designed to deliver the enhanced functionality and robust performance now demanded of this essential tool.
› Verified 7 days ago
Susan J Maturlo, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2874 N Carson St, Suite 120, Carson City, NV 89706 Phone: 775-445-7170 Fax: 775-687-8457 | |
Dr. David M Baker, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1470 Medical Pkwy, Suite 160, Carson City, NV 89703 Phone: 775-445-7650 Fax: 775-687-8457 | |
Dr. Stephen Michael Tann, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1470 Medical Parkway, Suite 160, Carson City, NV 89703 Phone: 775-445-7650 Fax: 775-882-4206 | |
Dr. Larry Angelo Pappas, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1600 Medical Pkwy, Carson City, NV 89703 Phone: 775-445-8000 | |
Dr. Christopher J Dipaolo, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1470 Medical Pkwy, Suite 160, Carson City, NV 89703 Phone: 775-445-7650 Fax: 775-687-8457 | |
Richard I Yamamoto, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2874 N Carson St, Suite 200, Carson City, NV 89706 Phone: 775-445-7170 Fax: 775-883-0959 | |
Dr. Christopher W Forman, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2874 N Carson St, Suite 200, Carson City, NV 89706 Phone: 775-445-7170 Fax: 775-883-0959 |